GlassScriptPhysician profile
Omar Longoria
NPI 1952061988
$6,985.57
in general payments reported to CMS, 2019-2025
26 companies · $5,155 in 2025
The $5,155 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $320 · 2023: $597 · 2024: $914 · 2025: $5,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108 · Consulting Fee: $2,450 · Travel and Lodging: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.13 |
| Consulting Fee | $2,450.00 |
| Travel and Lodging | $1,107.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,369.76 | 2024-2025 | Yeztugo, Descovy |
| Novo Nordisk INC | $913.93 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $316.27 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $192.84 | 2023-2025 | Airsupra, Farxiga |
| Abbvie INC. | $162.50 | 2022-2025 | |
| Viiv Healthcare Company | $144.70 | 2024-2025 | Apretude |
| Intuity Medical INC | $124.49 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Astellas Pharma US INC | $111.84 | 2024-2025 | Veozah |
| Amgen INC. | $69.56 | 2024-2025 | Repatha, Otezla, Repatha |
| Jazz Pharmaceuticals INC. | $64.01 | 2024-2025 | |
| Glaxosmithkline, LLC. | $62.32 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $60.74 | 2024-2025 | Gemtesa |
| Averitas Pharma INC. | $58.17 | 2024 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $50.97 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $45.53 | 2023-2024 | Xarelto |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $34.71 | 2022-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $26.29 | 2022 | |
| Horizon Therapeutics Plc | $25.23 | 2022 | |
| Inspire Medical Systems, INC. | $23.17 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $21.93 | 2022 | |
| Bioventus LLC | $21.18 | 2025 | Gelsyn-3 |
| Boston Scientific Corporation | $20.73 | 2025 | Cds - Mct/Cem Monitoring |
| Biohaven Pharmaceutical Holding Company LTD. | $19.23 | 2022 | |
| Pfizer INC. | $16.03 | 2025 | |
| Daiichi Sankyo INC. | $15.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.85 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Longoria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.